The JAK2V617F mutation, which leads to the constitutive activation of JAK2-associated cytokine receptor signaling, was originally recognized as being frequently mutated in myeloproliferative neoplasms (MPN) such as polycythemia vera and essential thrombocytosis. The gene discussed is JAK2; the disease is myeloproliferative disorder.